VERA Stock Surges After Drug To Treat Rare Kidney Disease Gets FDA Approval – Retail Sees The Move As Catalyst For Vera Therapeutics
Vera Therapeutics' Trutakna received an early, fast-tracked approval from the FDA to reduce proteinuria in adults with primary IgA Nephropathy whose health is at risk of deterioration.
Read the full articleYou might also wanna read
STAT+: FDA approves Vera Therapeutics kidney disease treatment
The FDA approved a new medicine from the biotech company Vera Therapeutics for patients with a type of chronic autoimmune kidney disease.
<![CDATA[FDA Approves Atacicept-vymj to Reduce Proteinuria in IgA Nephropathy]]>
Untitled
Telitacicept, a fusion protein targeting BAFF and APRIL, shows promise for IgA nephropathy in a phase 3 trial. Proteinuria ≥1.0 g/day addres
AstraZeneca autosomal dominant polycystic kidney disease drug gets orphan status
See the rest of the story here . thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The F
FDA approves Sanofi drug delivered with Enable on-body device
Sanofi announced today that the FDA approved the delivery of its Sarclisa anticancer therapy through the Enable Injections on-body device. S
US FDA approves AbbVie's rare blood cancer drug
US FDA approves AbbVie's rare blood cancer drug reut.rs/4tTXtZ3
Comments
Sign in to join the conversation.
No comments yet. Be the first.